Clinical Trials
Mechanisms of Immune Checkpoint Inhibitor Cancer Therapy-Associated and Spontaneous Thyroid Autoimmune Disease
PI: Dr. Lechner IRB#21-000633 (Sponsors: UCLA, USC, NIH and Aramont Charitable Foundation)
​
Immune related adverse events are autoimmune toxicities that occur in many patients treated with immune checkpoint inhibitor (ICI) cancer therapies, and the thyroid is one of the most common organs affected. In addition, thyroid autoimmune disease affects millions of individuals worldwide and leads to the need for lifelong thyroid hormone replacement. Our studies seek to determine the cause of these thyroid autoimmune diseases so that disease modifying therapies can be developed.
​
Involvement: The study involves collection of peripheral blood and a thyroid fine needle aspirate. Compensation is provided.
Eligibility: Adults with active thyroid disease, including immune checkpoint inhibitor thyroid disease, autoimmune thyroid disease (such as Hashimoto’s or thyroiditis). Controls without thyroid autoimmune disease are also needed, and can include individuals with benign thyroid nodules.
Sites: UCLA and USC
​
​
Immune Profiles Associated with Development of Immune Toxicities in Checkpoint Immunotherapy-Treated Cancer Patients
PI: Dr. Lechner IRB#20-000494 (Sponsors: UCLA, NIH)
​
Immune related adverse events are autoimmune toxicities that occur in many patients treated with immune checkpoint inhibitor (ICI) cancer therapies. Our studies seek to determine the cause of these IrAEs by following immune changes over time in patients treated with ICI while monitoring for the development of IrAEs and potential biomarkers for these unwanted side effects.
​
Involvement: The study involves collection of peripheral blood every 3 months for 1 year. Blood collection can be done in conjunction with Oncology visits.
Eligibility: Adults with cancer being treated with immune checkpoint inhibitor therapy.
Sites: UCLA and USC
​
​
Mechanisms of Autoimmunity
PI: Dr. Su IRB#19-000032 (Sponsors: UCLA, NIH)
​
This study examines the immune system changes that lead to the development of autoimmune diseases, specifically the role of T cells and myeloid cells, so that disease modifying therapies can be identified.
​
Involvement: The study involves collection of peripheral blood.
Eligibility: Children and adults with autoimmune disease, such as type 1 diabetes mellitus, autoimmune polyglandular syndrome (APS), Addison’s disease, thyroid autoimmune disease, and immunotherapy-related autoimmune disease.
Controls without autoimmune disease are also eligible.
Sites: UCLA and USC
​
​